
South and Central America Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory
Description
South and Central America Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)
The South and Central America carbapenem-based antibiotics market is expected to reach US$ 360.29 million by 2028 from US$ 281.43 million in 2021; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028.
The market's growth is attributed to factors such as rising prevalence of bacterial infections and increasing development of generic drugs. However, the tedious and expensive process for the development of antibiotics is expected to restrain the market's growth during the forecast years.
Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTIs and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTIs, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing.
In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years.
According to the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic led to the rise in HAI cases in 2020. Hospital admissions have grown globally, which has increased the risk of VAP as a secondary infection for COVID-19 patients. This has resulted in fueled demand for carbapenem-based antibiotics, which is aiding the market significantly.South and Central America Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)
SOUTH AND CENTRAL AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION
By Type
Meropenem
Imipenem
Doripenem
Tebipenem
Others By Indication
Bacterial Meningitis
Acute Pelvic Infections
Respiratory Tract Infections
Intra-Abdominal Infections
Urinary Tract Infections
Others By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies By Country
Brazil
Argentina
Rest of South and Central America Company Profiles
ACS Dobfar S.p.A
Gland Pharma Limited
Merck & Co., Inc.
Savior Lifetec
Pfizer Inc.
Spero Therapeutics
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South and Central America carbapenem-based antibiotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South and Central America carbapenem-based antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
The South and Central America carbapenem-based antibiotics market is expected to reach US$ 360.29 million by 2028 from US$ 281.43 million in 2021; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028.
The market's growth is attributed to factors such as rising prevalence of bacterial infections and increasing development of generic drugs. However, the tedious and expensive process for the development of antibiotics is expected to restrain the market's growth during the forecast years.
Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTIs and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTIs, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing.
In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years.
According to the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic led to the rise in HAI cases in 2020. Hospital admissions have grown globally, which has increased the risk of VAP as a secondary infection for COVID-19 patients. This has resulted in fueled demand for carbapenem-based antibiotics, which is aiding the market significantly.South and Central America Carbapenem-Based Antibiotics Market Revenue and Forecast to 2028 (US$ million)
SOUTH AND CENTRAL AMERICA CARBAPENEM-BASED ANTIBIOTICS MARKET SEGMENTATION
By Type
Meropenem
Imipenem
Doripenem
Tebipenem
Others By Indication
Bacterial Meningitis
Acute Pelvic Infections
Respiratory Tract Infections
Intra-Abdominal Infections
Urinary Tract Infections
Others By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies By Country
Brazil
Argentina
Rest of South and Central America Company Profiles
ACS Dobfar S.p.A
Gland Pharma Limited
Merck & Co., Inc.
Savior Lifetec
Pfizer Inc.
Spero Therapeutics
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South and Central America carbapenem-based antibiotics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the South and Central America carbapenem-based antibiotics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
124 Pages
- 1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 South and Central America Carbapenem-based Antibiotics Market – By Type
- 1.3.2 South and Central America Carbapenem-based Antibiotics Market – By Indication
- 1.3.3 South and Central America Carbapenem-based Antibiotics Market – By Distribution Channel
- 1.3.4 South and Central America Carbapenem-based Antibiotics Market – By Country
- 2. Carbapenem-based Antibiotics Market – Key Takeaways
- 3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
- 4. South and Central America Carbapenem-based Antibiotics Market – Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 South and Central America– PEST Analysis
- 4.3 Expert Opinions
- 5. Carbapenem-based Antibiotics Market – Key Market Dynamics
- 5.1 Drivers
- 5.1.1 Rising Prevalence of Gram-Negative Bacterial Infections
- 5.1.2 Increasing Production of Generic Drugs
- 5.2 Market Restraints
- 5.2.1 Tedious and Expensive Process of Antibiotic Development
- 5.3 Market Opportunities
- 5.3.1 Private and Public Partnerships
- 5.4 Future Trends
- 5.4.1 Strategic Advancement for New Antibiotic Identification
- 5.5 Impact Analysis
- 6. Carbapenem-based Antibiotics Market –South and Central America Analysis
- 6.1 South and Central America Carbapenem-based Antibiotics Market Revenue Forecast and Analysis
- 7. Carbapenem-based Antibiotics Market Analysis – By Type
- 7.1 Overview
- 7.2 Carbapenem-based Antibiotics Market Revenue Share, by Type (2021 and 2028)
- 7.3 Meropenem
- 7.3.1 Overview
- 7.3.2 Meropenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 7.4 Doripenem
- 7.4.1 Overview
- 7.4.2 Doripenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 7.5 Imipenem
- 7.5.1 Overview
- 7.5.2 Imipenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 7.6 Tebipenem
- 7.6.1 Overview
- 7.6.2 Tebipenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 8. Carbapenem-based Antibiotics Market – By Indication
- 8.1 Overview
- 8.2 Carbapenem-based Antibiotics Market, by Indication, 2021 and 2028 (%)
- 8.3 Bacterial Meningitis
- 8.3.1 Overview
- 8.3.2 Bacterial Meningitis: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 8.4 Acute Pelvic Infections
- 8.4.1 Overview
- 8.4.2 Acute Pelvic Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 8.5 Respiratory Tract Infections
- 8.5.1 Overview
- 8.5.2 Respiratory Tract Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 8.6 Intra-abdominal Infections
- 8.6.1 Overview
- 8.6.2 Intra-abdominal Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 8.7 Urinary Tract Infections
- 8.7.1 Overview
- 8.7.2 Urinary Tract Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 9. Carbapenem-based Antibiotics Market – By Distribution Channel
- 9.1 Overview
- 9.2 Carbapenem-based Antibiotics Market, by Distribution Channel, 2021 and 2028 (%)
- 9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Retail Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.4 Online Pharmacies
- 9.4.1 Overview
- 9.4.2 Online Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 9.5 Hospital Pharmacies
- 9.5.1 Overview
- 9.5.2 Hospital Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- 10. Carbapenem-based Antibiotics Market –Country Analysis
- 10.1 South and Central America: Carbapenem-based Antibiotics Market
- 10.1.1 Overview
- 10.1.2 South and Central America: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.3 South and Central America: Carbapenem-based Antibiotics Market, by Type, 2019–2028 (US$ ‘Million)
- 10.1.4 South and Central America: Carbapenem-based Antibiotics Market, by Indication, 2019–2028 (US$ Million)
- 10.1.5 South and Central America: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019–2028 (US$ Million)
- 10.1.6 South and Central America: Carbapenem-based Antibiotics Market, by Country, 2021 & 2028 (%)
- 10.1.6.1 Brazil: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.1.1 Brazil: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.1.2 Brazil: Carbapenem-based Antibiotics Market, by Type, 2019–2028 (US$ ‘Million)
- 10.1.6.1.3 Brazil: Carbapenem-based Antibiotics Market, by Indication, 2019–2028 (US$ ‘Million)
- 10.1.6.1.4 Brazil: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019–2028 (US$ ‘Million)
- 10.1.6.2 Argentina: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.2.1 Argentina: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.2.2 Argentina: Carbapenem-based Antibiotics Market, by Type, 2019–2028 (US$ ‘Million)
- 10.1.6.2.3 Argentina: Carbapenem-based Antibiotics Market, by Indication, 2019–2028 (US$ ‘Million)
- 10.1.6.2.4 Argentina: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019–2028 (US$ ‘Million)
- 10.1.6.3 Rest of South and Central America: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.3.1 Rest of South and Central America: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- 10.1.6.3.2 Rest of South and Central America: Carbapenem-based Antibiotics Market, by Type, 2019–2028 (US$ ‘Million)
- 10.1.6.3.3 Rest of South and Central America: Carbapenem-based Antibiotics Market, by Indication, 2019–2028 (US$ ‘Million)
- 10.1.6.3.4 Rest of South and Central America: Carbapenem-based Antibiotics Market, by Distribution Channel, 2019–2028 (US$ ‘Million)
- 11. Impact of COVID-19 Pandemic on Carbapenem-based Antibiotics Market
- 11.1 South and Central America: Impact Assessment of COVID-19 Pandemic
- 12. Carbapenem-based Antibiotics Market–Industry Landscape
- 12.1 Overview
- 12.2 Organic Developments
- 12.2.1 Overview
- 12.3 Inorganic Developments
- 12.3.1 Overview
- 13. COMPANY PROFILES
- 13.1 ACS Dobfar S.p.A
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
- 13.2 Gland Pharma Limited
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
- 13.3 Merck & Co., Inc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
- 13.4 Savior Lifetec
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
- 13.5 Pfizer Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
- 13.6 Spero Therapeutics
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
- 14. Appendix
- 14.1 About The Insight Partners
- 14.2 Glossary of Terms
- List of Tables
- Table 1. South and Central America: Carbapenem-based Antibiotics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 2. South and Central America: Carbapenem-based Antibiotics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
- Table 3. South and Central America: Carbapenem-based Antibiotics Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
- Table 4. Brazil: Carbapenem-based Antibiotics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 5. Brazil: Carbapenem-based Antibiotics Market, by Indication – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 6. Brazil: Carbapenem-based Antibiotics Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 7. Argentina: Carbapenem-based Antibiotics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 8. Argentina: Carbapenem-based Antibiotics Market, by Indication – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 9. Argentina: Carbapenem-based Antibiotics Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 10. Rest of South and Central America: Carbapenem-based Antibiotics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 11. Rest of South and Central America: Carbapenem-based Antibiotics Market, by Indication – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 12. Rest of South and Central America: Carbapenem-based Antibiotics Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ ‘Million)
- Table 13. Organic Developments in the Carbapenem-based Antibiotics Market
- Table 14. Inorganic Developments in the Carbapenem-based Antibiotics Market
- Table 15. Glossary of Terms, Carbapenem-based Antibiotics Market
- List of Figures
- Figure 1. Carbapenem-based Antibiotics Market Segmentation
- Figure 2. Carbapenem-based Antibiotics Segmentation, By Country
- Figure 3. South and Central America Carbapenem-based Antibiotics Market Overview
- Figure 4. The Others Segment Held Largest Share of Type Segment in Carbapenem-based Antibiotics Market
- Figure 5. South and Central America Carbapenem-based Antibiotics Market- Leading Country Markets (US$ Million)
- Figure 6. South and Central America PEST Analysis
- Figure 7. Carbapenem-based Antibiotics Market Impact Analysis of Driver and Restraints
- Figure 8. South and Central America Carbapenem-based Antibiotics Market – Revenue Forecast and Analysis – 2021- 2028
- Figure 9. Carbapenem-based Antibiotics Market Revenue Share, by Type (2021 and 2028)
- Figure 10. Meropenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 11. Doripenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 12. Imipenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 13. Tebipenem: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 14. Others: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 15. Carbapenem-based Antibiotics Market, by Indication, 2021 and 2028 (%)
- Figure 16. Bacterial Meningitis: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 17. Acute Pelvic Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 18. Respiratory Tract Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 19. Intra-abdominal Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 20. Urinary Tract Infections: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 21. Others: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 22. Carbapenem-based Antibiotics Market, by Distribution Channel, 2021 and 2028 (%)
- Figure 23. Retail Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 24. Online Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 25. Hospital Pharmacies: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ Million)
- Figure 26. South and Central America: Carbapenem-based Antibiotics Market, by Key Country – Revenue (2021) (US$ ‘Million)
- Figure 27. South and Central America: Carbapenem-based Antibiotics Market Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 28. South and Central America: Carbapenem-based Antibiotics Market, by Country, 2021 & 2028 (%)
- Figure 29. Brazil: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 30. Argentina: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 31. Rest of South and Central America: Carbapenem-based Antibiotics Market – Revenue and Forecast to 2028 (US$ ‘Million)
- Figure 32. Impact Of COVID-19 Pandemic in South and Central America Country Markets
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.